Bio-Path Hldgs Inc Stock Price, News & Analysis

Bio-Path Holdings, Inc. (NASDAQ: BPTH) has announced a registered direct offering of 800,000 shares of common stock at $2.50 per share, aiming for gross proceeds of approximately $2 million. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 800,000 shares at an exercise price of $2.85 per share. The offerings are expected to close around November 9, 2022. Proceeds will be allocated for working capital and general corporate purposes, bolstering their development of targeted nucleic acid cancer drugs using the DNAbilize technology.

Bio-Path Holdings announced the first patient enrollment in a Phase 1/1b clinical trial for BP1002, targeting venetoclax-resistant acute myeloid leukemia (AML) patients. This trial aims to assess BP1002's ability to inhibit Bcl-2 protein, which is linked to poor prognosis in AML. The trial includes notable cancer centers and plans to evaluate BP1002 in combination with decitabine after initial monotherapy. The outcome of this trial could significantly impact treatment options for patients with limited life expectancy.

Bio-Path Holdings, a biotechnology firm focused on developing targeted nucleic acid cancer drugs, announced that CEO Peter Nielsen will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. The presentation will be available as a pre-recorded audio webcast starting at 7:00 a.m. ET and can be accessed on the company's website. Bio-Path's lead candidate, prexigebersen, is in a Phase 2 trial for blood cancers, while other products are in various stages of development, aiming to target specific cancer proteins.

Bio-Path Holdings, Inc. (NASDAQ:BPTH) reported its financial results for Q2 2022, posting a net loss of $3.0 million or $0.42 per share, up from a net loss of $1.8 million in Q2 2021. Research and development expenses grew to $1.9 million due to increased clinical trial activities. Cash reserves decreased to $17.0 million as of June 30, 2022. The company anticipates commencing Phase 1 studies for BP1001-A and BP1002 shortly and presented encouraging preclinical data for BP1003 at the AACR Annual Meeting.

Bio-Path Holdings (NASDAQ: BPTH) will host a live conference call on August 16, 2022, at 8:30 a.m. ET to discuss its Q2 financial results and provide a business overview. The call can be accessed by calling (833) 630-1956 domestically or (412) 317-1837 internationally. Additionally, a live audio webcast will be available on the company's website, with an archived version posted two hours afterward. Bio-Path is focused on developing DNAbilize^®, a proprietary RNAi nanoparticle technology, targeting cancer therapies.

Bio-Path Holdings (NASDAQ: BPTH) announced its first-quarter financial results for 2022, reporting a net loss of $3.4 million or $0.47 per share, compared to a loss of $2.4 million or $0.43 per share in Q1 2021. The company saw increased R&D expenses of $2.1 million, mainly due to clinical trial costs, and general administrative expenses rose to $1.3 million. Cash reserves stood at $21.2 million as of March 31, 2022. Notably, Bio-Path presented promising preclinical data for its drug candidate BP1003 at the AACR Annual Meeting, indicating potential effectiveness in treating difficult cancers.

Bio-Path Holdings (NASDAQ: BPTH) will hold a conference call on May 17, 2022, at 8:30 a.m. ET to discuss its Q1 financial results for the period ending March 31, 2022. The call will offer a business overview and can be accessed by phone or via a live audio webcast on the company's website. Bio-Path is advancing its proprietary DNAbilize^® technology, with lead candidate prexigebersen in a Phase 2 study for blood cancers and plans for Phase 1 studies of BP1001-A in solid tumors. The company aims to file an IND for BP1003 in 2022.

Bio-Path Holdings (NASDAQ: BPTH) presented preclinical data for BP1003, a novel cancer therapy, at the 2022 AACR Annual Meeting. The findings suggest that BP1003 enhances the efficacy of standard chemotherapies like paclitaxel and 5-FU in treating breast and ovarian cancers. CEO Peter Nielsen expressed excitement about these results, indicating plans to file an IND application and initiate clinical studies for BP1003. The drug targets the STAT3 pathway, which is associated with cancer progression and drug resistance, showcasing potential for advanced solid tumor treatment.

Bio-Path Holdings, Inc. (NASDAQ: BPTH) appointed Aline Sherwood to its Board of Directors on March 31, 2022, following the resignation of Martina Molsbergen on February 14, 2022. Sherwood, a seasoned communications leader with extensive biotech experience, will help enhance the company's messaging in the clinical and financial sectors. Her role is expected to support Bio-Path's advancement in developing cancer therapies using its proprietary DNAbilize^® technology. The company is focused on critical cancer treatments, with several candidates currently in trials.